Anika Therapeutics (ANIK) Shares Outstanding (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Shares Outstanding (Entity) of $13.4 million for Q2 2026, down 7.18% year-over-year from $14.4 million in Q2 2025, and little changed quarter-over-quarter from $13.4 million in Q1 2026.
Anika Therapeutics (ANIK) Shares Outstanding (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Shares Outstanding (Entity) for 17 consecutive years, with $13.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) fell 7.18% year-over-year to $13.4 million; the TTM figure through Jun 2026 stood at $13.4 million (down 7.18% YoY), while the FY2025 annual figure was $13.9 million, down 3.66% from the prior year.
- Shares Outstanding (Entity) steadied at $13.4 million in Q2 2026 per ANIK's latest filing, from $13.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $14.8 million in Q2 2024 and bottomed at $13.4 million in Q1 2026.
- Historically, Shares Outstanding (Entity) has averaged $14.4 million across 5 years, with a median of $14.6 million in 2022.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) rose 1.54% — and 2026, when it slipped 7.18%.
- Anika Therapeutics' Shares Outstanding (Entity) stood at $14.6 million in 2022, then climbed by 0.24% to $14.7 million in 2023, then decreased by 1.66% to $14.4 million in 2024, then declined by 3.66% to $13.9 million in 2025, then dropped by 3.64% to $13.4 million in 2026.
- Business Quant data shows ANIK's Shares Outstanding (Entity) at $13.4 million in Q2 2026, $13.4 million in Q1 2026, and $13.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | Anika Therapeutics | 285.86 Mn | 247.45 Mn | 21.24 Mn | 13.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.33 Mn |
| Mar 31, 2026 | 13.53 Mn |
| Dec 31, 2025 | 14.34 Mn |
| Sep 30, 2025 | 14.42 Mn |
| Jun 30, 2025 | 14.36 Mn |
| Mar 31, 2025 | 14.30 Mn |
| Dec 31, 2024 | 14.72 Mn |
| Sep 30, 2024 | 14.77 Mn |
| Jun 30, 2024 | 14.84 Mn |
| Mar 31, 2024 | 14.70 Mn |
| Dec 31, 2023 | 14.66 Mn |
| Sep 30, 2023 | 14.64 Mn |
| Jun 30, 2023 | 14.69 Mn |
| Mar 31, 2023 | 14.65 Mn |
| Dec 31, 2022 | 14.56 Mn |
| Sep 30, 2022 | 14.60 Mn |
| Jun 30, 2022 | 14.56 Mn |
| Mar 31, 2022 | 14.47 Mn |
| Dec 31, 2021 | 14.40 Mn |
| Sep 30, 2021 | 14.43 Mn |